Previous close | 2.4200 |
Open | 2.3800 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 2.3600 - 2.5200 |
52-week range | 0.6650 - 4.9500 |
Volume | |
Avg. volume | 41,677 |
Market cap | 13.149M |
Beta (5Y monthly) | 0.13 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.1000 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Completion of the novel epidural continuous glucose monitoring study confirms its potential for providing simplified disease management for patients with painful diabetic neuropathy Rutherford, NJ, June 13, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical device company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that its implantable continuous glucose monitor has succ
Rutherford, NJ, June 10, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people with diabetes, today announced that it will participate in the Sidoti Small Cap Investor Conference. Paul V. Goode, CEO of Glucotrack, will present on Wednesday, June 12, 2024 at 3:15 PM ET and will hold one-on-one meetings. Interested parties may register using th
Highly accurate continuous blood glucose monitor demonstrates Mean Absolute Relative Difference (MARD) of 4.7% at Day 90 Continuous blood glucose monitor offers the potential for simplified, discreet and less intrusive glucose monitoring for people with diabetes Rutherford, NJ, June 05, 2024 (GLOBE NEWSWIRE) -- Glucotrack, Inc. (Nasdaq: GCTK) (“Glucotrack” or the “Company”), a medical technology company focused on the design, development, and commercialization of novel technologies for people wi